If you have been reading about NR1D1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-20. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Mary Wortley Montagu, who had witnessed variolation in Turkey, had her four-year-old daughter variolated in the presence of physicians of the Royal Court in 1721 upon her return to England. Later on that year, Charles Maitland conducted an experimental variolation of six prisoners in Newgate Prison in London. The experiment was a success, and soon variolation was drawing attention from the royal family, who helped promote the procedure. However, in 1783, several days after Prince Octavius of Great Britain was inoculated, he died. In 1796, the physician Edward Jenner took pus from the hand of a milkmaid with cowpox, scratched it into the arm of an 8-year-old boy, James Phipps, and six weeks later variolated the boy with smallpox, afterwards observing that he did not catch smallpox. Jenner extended his studies and, in 1798, reported that his vaccine was safe in children and adults, and could be transferred from arm-to-arm, which reduced reliance on uncertain supplies from infected cows. In 1804, the Spanish Balmis smallpox vaccination expedition to Spain's colonies Mexico and Philippines used the arm-to-arm transport method to get around the fact the vaccine survived for only 12 days in vitro. They used cowpox. Since vaccination with cowpox was much safer than smallpox inoculation, the latter, though still widely practiced in England, was banned in 1840.
Insectivores which fed on unsupplemented invertebrates have been found to suffer from vitamin A deficiencies, and a study of panther chameleons (Furcifer pardalis) found vitamin A deficiency shortened life spans and reduced reproduction rates. Turkestan cockroaches are rich in vitamin B12.
== Diagnosis == In addition to evaluating the symptoms above, the health care provider may find decreased or no blood pressure in the arm or leg. Tests to determine any underlying cause for thrombosis or embolism and to confirm presence of the obstruction may include:
Rourk's legislative platform emphasizes economic stability for working families, advocating for strengthening the Child Tax Credit, expanding technical workforce training and apprenticeships, and indexing the federal minimum wage to the cost of living. On healthcare, she favors a public option, permanently expanding Affordable Care Act (ACA) subsidies, and allowing Medicare to negotiate prescription drug price. Her broader policy priorities include fully funding public schools while opposing private school voucher expansions, establishing a federal accountability framework for AI data center infrastructure, and passing comprehensive immigration reform that combines border enforcement with an earned path to citizenship for law-abiding residents.
Sources: en.wikipedia.org
==== Vietnam and wide tobacco-related costs ==== In Vietnam, the e-cigarette market is growing rapidly, with the use rate increasing 18 times from 2015 to 2020. The use rate of e-cigarettes in adolescents aged 13–15 is 3.5%, up 1.6% from 2019. According to estimates by the World Health Organization (WHO), the global economic losses caused by tobacco each year are $1.4 trillion. Economic losses caused by tobacco are estimated to account for 1% of GDP. The Vietnamese government is making efforts to control the e-cigarette market. However, here are still many challenges to be addressed, such as consumer's lack of understanding of the harm of e-cigarettes, unclear legal regulations, and fierce competition from imported e-cigarette products.
Prolargin is a protein that in humans is encoded by the PRELP gene. The protein encoded by this gene is a leucine-rich repeat protein present in connective tissue extracellular matrix. This protein functions as a molecule anchoring basement membranes to the underlying connective tissue. This protein has been shown to bind type I collagen to basement membranes and type II collagen to cartilage. It also binds the basement membrane heparan sulfate proteoglycan perlecan. This protein is suggested to be involved in the pathogenesis of Hutchinson–Gilford progeria (HGP), which is reported to lack the binding of collagen in basement membranes and cartilage. Alternatively spliced transcript variants encoding the same protein have been observed.
=== Bone Marrow === Bone marrow can be used for testing but that depends on the quality and availability of the bones. So far there is no proof that says that certain bones are better than others when it comes to testing. Extracting bone marrow from larger bones is easier than smaller bones. Forensic toxicologists often use bone marrow to find what type poisons used, which can include cocaine or ethanol. Ethanol specifically is one of the most abused drugs worldwide, be it through alcohol consumption and abuse being a leading cause in death. Suicides, car crashes, and a variety of crimes are often performed under severe alcohol influence. The process of ethanol determination allows forensic toxicologists to utilize bone marrow post-mortem and isolate the ethanol level a person had been, and the metabolic speed of breakdown at which can be traced back to time of death.
Supercritical drying Supercritical drying is reputed to be the most efficient drying technique but is rather expensive and difficult to implement. It was first implemented by Canham in 1994 and involves superheating the liquid pore above the critical point to avoid interfacial tension.
=== Obesity and metabolic syndrome === Ketosis can improve markers of metabolic syndrome through reduction in serum triglycerides, elevation in high-density lipoprotein (HDL) as well as increased size and volume of low-density lipoprotein (LDL) particles. These changes are consistent with an improved lipid profile despite potential increases in total cholesterol level.
Sources: en.wikipedia.org
== Non-enzymatic processes == Protein backbones are very stable in water at neutral pH and room temperature, although the rate of hydrolysis of different peptide bonds can vary. The half-life of a peptide bond under normal conditions can range from 7 years to 350 years, even higher for peptides protected by modified terminus or within the protein interior. The rate of hydrolysis however can be significantly increased by extremes of pH and heat. Spontaneous cleavage of proteins may also involve catalysis by zinc on serine and threonine. Strong mineral acids can readily hydrolyse the peptide bonds in a protein (acid hydrolysis). The standard way to hydrolyze a protein or peptide into its constituent amino acids for analysis is to heat it to 105 °C for around 24 hours in 6M hydrochloric acid. However, some proteins are resistant to acid hydrolysis. One well-known example is ribonuclease A, which can be purified by treating crude extracts with hot sulfuric acid so that other proteins become degraded while ribonuclease A is left intact. Certain chemicals cause proteolysis only after specific residues, and these can be used to selectively break down a protein into smaller polypeptides for laboratory analysis. For example, cyanogen bromide cleaves the peptide bond after a methionine. Similar methods may be used to specifically cleave tryptophanyl, aspartyl, cysteinyl, and asparaginyl peptide bonds. Acids such as trifluoroacetic acid and formic acid may be used for cleavage. Like other biomolecules, proteins can also be broken down by high heat alone.
Chemiluminescence (also chemoluminescence) is the emission of light (luminescence) as the result of a chemical reaction, i.e. a chemical reaction resulting in a flash or glow of light. A standard example of chemiluminescence in the laboratory setting is the luminol test wherein blood is indicated by luminescence upon contact with iron in hemoglobin. A light stick also emits light by chemiluminescence. When chemiluminescence takes place in living organisms, the phenomenon is called bioluminescence.
For voluntary service to St John Ambulance in London. Bronagh Mary Hegarty. Covid-19 Principal Pharmacist for Patient Services and Procurement, Western Health and Social Care Trust. For services to Healthcare and Pharmacy. Ian Bruce Henderson. Councillor, Kensington and Chelsea London Borough Council. For services to the community in the Royal Borough of Kensington and Chelsea. Jacqueline Ann Hendra. Social Care Assessor, Devon County Council. For services to People with Disabilities. Robert Patrick Hendry. Custodian, Prime Minister's Office. For services to the Prime Minister's Office. Daniel Herman. For services to Education and to Holocaust Awareness. Timothy John Hewer. For services to Beekeeping in Little Stoke, South Gloucestershire. Pauline Higgins. For services to the community in Liverpool, Merseyside. Donald Alexander Hill. For services to the community in County Londonderry. Felicity Ann De Grave Hills. For services to the community in Hastings, East Sussex. Andrew Richard Hinchliff. Lately Member, Conwy County Council. For services to Local Government and to the community in North Wales. Duncan Holden. Cricket Co-ordinator and Safeguarding Officer, Stoke Newington Cricket Club. For services to Sport in London. Ian Watson Holland. Lately Chair and Trustee, Enable Ayr and District SCIO. For services to People with Learning Disabilities in Ayr and Prestwick. Beverly Joan Hopkins. Special Educational Needs Co-ordinator, Palmerston Primary School, Barry. For services to Education, to People with Disabilities and to Sport. The Reverend Christopher Stewart Howson.
=== Protease Biology === Thanks to rapid advances in proteomics, genomics, and bioinformatics, protease research has been revolutionized. Degradomics emerged with the concept that proteolysis represents a specific mechanism for achieving cellular control over vital processes beyond control afforded by gene expression and translation and continues to produce the research necessary to understand the complex regulation of biology. Where it was thought extracellular proteases degraded extracellular matrix (ECM), these proteases are now known to target and process a vast array of substrates with diverse roles, redefining protease functions and leading to a shift in interest towards new roles previously unknown to biology. Degradomic studies of human tissue have also contributed to the Human Proteome Project (HPP) of the Human Proteome Organization (HUPO).
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.